Abstracts
PO48
Real-world (RW) Characteristics, Utilization, and Effectiveness Among Patients With Heavily Pre-treated Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Talquetamab in Large Community Oncology Practice
Introduction/Background/Significance: For patients with RRMM, outcomes worsen with each successive line of therapy (LOT). Talquetamab, a first-in-class GPRC5D×CD3 bispecific antibody, demonstrated clinically meaningful efficacy and safety outcomes in patients with RRMM in the phase 1/2 MonumenTAL-1 clinical trial. However, RW data for patients treated with talquetamab outside of clinical trials, especially within community practices, remains limited. This retrospective, observational study aimed to assess RW use of talquetamab at Texas Oncology, a large network of community oncology practices spanning 300 locations in Texas, USA.
Materials and Methods/Case Presentation/Objective:
Results/Description/Main Outcome Measure(s): Overall, 44 patients were included (median follow-up, 9.8 months). Median age was 67.5 years, with 61.4% aged ≥65 years. Of these patients, 56.8% were male, 65.9% were White, and 13.6% were Hispanic; 54.5% had a commercial payer and 15.9% had Medicare (Medicare FFS or Advantage). According to revised International Staging System guidelines, 15.9% of patients had Stage I disease, 13.6% had Stage II disease, and 59.1% had Stage III disease; 11.4% had disease of unknown stage. Most (65.9%) patients had high-risk cytogenetics, including del17p (34.1%), t(4;14) (13.6%), t(14;16) (6.8%), gain 1q21 (47.7%), and amp 1q21 (2.3%). Patients were heavily pre-treated, with a median (range) of 6 (3-14) prior LOTs at index. Most (84.1%) patients had prior exposure to B-cell maturation antigen therapy, including exposure to belantamab (9.1%), ciltacabtagene autoleucel (34.1%), idecabtagene vicleucel (27.3%), elranatamab (4.5%), and teclistamab (45.5%). The setting of talquetamab step-up dosing was inpatient (43.2%), hospital observation or outpatient (50.0%), and unknown (6.8%). Talquetamab was received primarily as monotherapy (84.1%), followed by bridging therapy (15.9%). Among patients with non-bridging talquetamab therapy (n=37), the treatment discontinuation rate at 9 months was 67.6%. Thirty patients discontinued; primary reasons for discontinuation were disease progression (54.1%), death (16.2%), adverse events/toxicity (5.4%), and other reasons (2.7%). Among patients with non-bridging talquetamab therapy, the overall response rate was 75.7% (partial response 29.7%, very good partial response 27.0%, and complete response or better 18.9%). Median time to best response was 1.8 months and median duration of response was 6.8 months, with a 9-month response rate of 42.6%.
Conclusion(s).: These RW data highlight the strong treatment response in patients with heavily pre-treated RRMM, ³4 prior LOTs, and high-risk cytogenetics receiving talquetamab in a large community setting; treatment was feasible and tolerable, time to response was short, and responses were durable
Trademarked Items:
References:
Materials and Methods/Case Presentation/Objective:
Adult patients with RRMM and ≥4 prior LOTs treated with talquetamab monotherapy or combination regimens between August 9, 2023 and June 30, 2025 were identified from databases of patients treated at Texas Oncology's community oncology practices. Patients receiving talquetamab as part of a clinical trial at any time were excluded. Patient characteristics were collected during the baseline period (12 months pre-index date). Patients were followed from the index date (talquetamab initiation) to the earliest of last activity date, death, or end of the data period (February 28, 2026). Descriptive statistics were used to summarize demographics, treatment characteristics, and clinical outcomes. Kaplan-Meier method was used to estimate duration of response.
Results/Description/Main Outcome Measure(s): Overall, 44 patients were included (median follow-up, 9.8 months). Median age was 67.5 years, with 61.4% aged ≥65 years. Of these patients, 56.8% were male, 65.9% were White, and 13.6% were Hispanic; 54.5% had a commercial payer and 15.9% had Medicare (Medicare FFS or Advantage). According to revised International Staging System guidelines, 15.9% of patients had Stage I disease, 13.6% had Stage II disease, and 59.1% had Stage III disease; 11.4% had disease of unknown stage. Most (65.9%) patients had high-risk cytogenetics, including del17p (34.1%), t(4;14) (13.6%), t(14;16) (6.8%), gain 1q21 (47.7%), and amp 1q21 (2.3%). Patients were heavily pre-treated, with a median (range) of 6 (3-14) prior LOTs at index. Most (84.1%) patients had prior exposure to B-cell maturation antigen therapy, including exposure to belantamab (9.1%), ciltacabtagene autoleucel (34.1%), idecabtagene vicleucel (27.3%), elranatamab (4.5%), and teclistamab (45.5%). The setting of talquetamab step-up dosing was inpatient (43.2%), hospital observation or outpatient (50.0%), and unknown (6.8%). Talquetamab was received primarily as monotherapy (84.1%), followed by bridging therapy (15.9%). Among patients with non-bridging talquetamab therapy (n=37), the treatment discontinuation rate at 9 months was 67.6%. Thirty patients discontinued; primary reasons for discontinuation were disease progression (54.1%), death (16.2%), adverse events/toxicity (5.4%), and other reasons (2.7%). Among patients with non-bridging talquetamab therapy, the overall response rate was 75.7% (partial response 29.7%, very good partial response 27.0%, and complete response or better 18.9%). Median time to best response was 1.8 months and median duration of response was 6.8 months, with a 9-month response rate of 42.6%.
Conclusion(s).: These RW data highlight the strong treatment response in patients with heavily pre-treated RRMM, ³4 prior LOTs, and high-risk cytogenetics receiving talquetamab in a large community setting; treatment was feasible and tolerable, time to response was short, and responses were durable
Trademarked Items:
References:
